Phaseline

Companies › Intervene Immune

Intervene Immune: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRIIM Treatment
Combination of somatropin (recombinant human growth hormone), metformin, and DHEA
GH1, AMPKPhase 2Epigenetic Aging–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04375657TRIIM TreatmentPhase 2Epigenetic AgingOtherDec 2025

Targets

GH1 (1) AMPK (1)

Companies with the same targets

Kexing Biopharm Xiamen Amoytop Biotech Changchun GeneScience Pharmaceutical

Companies built like this

Serum Life Science Europe Distribuidora Biolife SA de CV Circul'Egg Biosolution Photozig

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.